Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Accenture
Farmers Insurance
Fuji
Fish and Richardson
Johnson and Johnson
Baxter
AstraZeneca
McKinsey
Cantor Fitzgerald

Generated: October 17, 2017

DrugPatentWatch Database Preview

Azelastine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for azelastine hydrochloride and what is the scope of azelastine hydrochloride freedom to operate?

Azelastine hydrochloride
is the generic ingredient in six branded drugs marketed by Mylan Speciality Lp, Sandoz Inc, Upsher-smith Labs, Zydus Pharms Usa Inc, Apotex Inc, Sun Pharma Global, Perrigo Israel, West-ward Pharms Int, Alkem Labs Ltd, Akorn, Amneal Pharms Llc, and Breckenridge Pharm, and is included in twenty NDAs. There are five patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Azelastine hydrochloride has forty patent family members in twenty countries and four supplementary protection certificates in four countries.

There are twelve drug master file entries for azelastine hydrochloride. Fifteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: azelastine hydrochloride

US Patents:5
Tradenames:6
Applicants:12
NDAs:20
Drug Master File Entries: see list12
Suppliers / Packagers: see list15
Bulk Api Vendors: see list92
Clinical Trials: see list2,295
Patent Applications: see list5,983
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:azelastine hydrochloride at DailyMed

Pharmacology for Ingredient: azelastine hydrochloride

Tentative approvals for AZELASTINE HYDROCHLORIDE

Applicant Application No. Strength Dosage Form
u► SubscribeEQ 0.1876MG BASE/SPRAYSPRAY, METERED;NASAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms Usa Inc
AZELASTINE HYDROCHLORIDE
azelastine hydrochloride
SPRAY, METERED;NASAL091409-001Aug 14, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Speciality Lp
ASTEPRO
azelastine hydrochloride
SPRAY, METERED;NASAL022203-001Oct 15, 2008DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo Israel
AZELASTINE HYDROCHLORIDE
azelastine hydrochloride
SPRAY, METERED;NASAL202743-001May 8, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Speciality Lp
ASTEPRO
azelastine hydrochloride
SPRAY, METERED;NASAL022203-001Oct 15, 2008DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Alkem Labs Ltd
AZELASTINE HYDROCHLORIDE
azelastine hydrochloride
SPRAY, METERED;NASAL208156-001Aug 18, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
AZELASTINE HYDROCHLORIDE
azelastine hydrochloride
SPRAY, METERED;NASAL077954-001Apr 30, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Speciality Lp
ASTEPRO
azelastine hydrochloride
SPRAY, METERED;NASAL022203-002Aug 31, 2009ABRXYesYes► Subscribe► Subscribe ► Subscribe
Akorn
AZELASTINE HYDROCHLORIDE
azelastine hydrochloride
SOLUTION/DROPS;OPHTHALMIC203660-001Nov 8, 2016ATRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Speciality Lp
ASTEPRO
azelastine hydrochloride
SPRAY, METERED;NASAL022203-002Aug 31, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Breckenridge Pharm
AZELASTINE HYDROCHLORIDE
azelastine hydrochloride
SPRAY, METERED;NASAL090176-001Jul 28, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: azelastine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Speciality Lp
ASTELIN
azelastine hydrochloride
SPRAY, METERED;NASAL020114-001Nov 1, 1996► Subscribe► Subscribe
Mylan Speciality Lp
OPTIVAR
azelastine hydrochloride
SOLUTION/DROPS;OPHTHALMIC021127-001May 22, 2000► Subscribe► Subscribe
Mylan Speciality Lp
OPTIVAR
azelastine hydrochloride
SOLUTION/DROPS;OPHTHALMIC021127-001May 22, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: azelastine hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,758,816Compositions comprising azelastine and methods of use thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: azelastine hydrochloride

Country Document Number Estimated Expiration
Denmark2522365► Subscribe
Australia2012201428► Subscribe
European Patent Office2486942► Subscribe
Portugal2522365► Subscribe
Poland2522365► Subscribe
Hong Kong1113310► Subscribe
Spain2617255► Subscribe
World Intellectual Property Organization (WIPO)2006058022► Subscribe
BrazilPI0517891► Subscribe
HungaryE030388► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: AZELASTINE HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00740Netherlands► SubscribePRODUCT NAME: AZELASTINE OF EEN; NAT. REGISTRATION NO/DATE: RVG114215 20141125; FIRST REGISTRATION: 2011/07125-REG 20130215
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C0012Belgium► SubscribePRODUCT NAME: AZELASTINE HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 31 IS 113 F 13 19981021; FIRST REGISTRATION: GB PL 08336/0083 19980218
C0067France► SubscribePRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Farmers Insurance
Express Scripts
Federal Trade Commission
Harvard Business School
AstraZeneca
Fuji
QuintilesIMS
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot